Zdrowie i gospodarka · 01/08/2003

FDA Releases Guidance on 180-Day Exclusivity for Multiple ANDA Submissions

The Food and Drug Administration (FDA) has released a guidance document explaining how it will determine eligibility for 180-day exclusivity when multiple abbreviated new drug applications (ANDAs) containing paragraph IV certifications are submitted on the same day or in amendments/supplements.